BC Week In Review | Jun 16, 2017
Company News

GeneriCo wins IPR for Apriso

In a May inter partes review (IPR) proceeding, the U.S. Patent Trial and Appeal Board (PTAB) invalidated all claims in U.S. Patent 8,865,688 covering ulcerative colitis (UC) drug Apriso granulated mesalamine from Valeant Pharmaceuticals International...
BioCentury | Nov 10, 2014

Convert resurgence

Biotechs have raised $5.6 billion through convertible debt financings so far this year, the highest amount since 2006. Two bankers attributed the resurgence to a growing mid-cap space that is taking advantage of low interest...
BC Extra | Nov 7, 2014
Top Story

Salix hit on accounting turmoil

Salix Pharmaceuticals Ltd. (NASDAQ:SLXP) plunged $53.05 (38%) to $85.50 in after-hours trading on Thursday on news its CFO had resigned and the company had retained outside counsel to investigate how it was accounting for inventory...
BioCentury | Aug 11, 2014

Highlights of weekly biotech stock moves

Regulatory milestones Biodefense company Emergent BioSolutions Inc. (NYSE:EBS) was up $0.44 to $22.47 last week after submitting a BLA to FDA for Anthrax immune globulin IV (AIGIV) to treat inhaled anthrax. AIGIV is being developed...
BioCentury | May 12, 2014

Zeroing in on immunity

Investors in Anokion S.A. 's CHF33 million ($37.6 million) series A round think the company's antigen-specific approach to inducing immune tolerance will lead to less immunogenic formulations of existing cancer and hematology drugs, as well...
BioCentury | Mar 3, 2014

Spreading six

Abingworth's sixth flagship fund likely will put more money towards the opposite ends of the firm's investment universe - start-ups and public companies. The new fund closed last week at £225 million ($375 million). Seven years...
BioCentury | Nov 11, 2013

OrbiMed's high five

At a time when many life science VCs are raising smaller funds, OrbiMed Advisors closed what might be the largest pure venture fund in over a decade, raising more than $735 million from LPs who...
BioCentury | Aug 12, 2013

Signed and sealed

ProFibrix B.V. reached the one-yard line with its Fibrocaps based on €40 million in equity funding, but rather than amass commercial scale to compete in the surgical products market, the company accepted a takeout bid...
BioCentury | May 13, 2013

Watch me launch

Isis Pharmaceuticals Inc. (NASDAQ:ISIS) didn't wait for investors to learn launch details of hypercholesterolemia drug Kynamro mipomersen. Instead, the biotech took advantage of recent share price gains to raise $171 million in the largest follow-on...
BioCentury | Mar 4, 2013

Amgen's Omontys bounce

Amgen Inc. (NASDAQ:AMGN) added $2 billion in market cap last Monday, which was nearly four times the value shaved off competitor Affymax Inc. (NASDAQ:AFFY) when the latter recalled its once-monthly anemia drug Omontys peginesatide. Amgen...
Items per page:
1 - 10 of 31